@article{TLCR28795,
author = {Jose M. Pacheco},
title = {KEYNOTE-042: is lowering the PD-L1 threshold for first-line pembrolizumab monotherapy a good idea?},
journal = {Translational Lung Cancer Research},
volume = {8},
number = {5},
year = {2019},
keywords = {},
abstract = {Prior to the advent of inhibitory antibodies targeting programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1), the median overall survival (OS) for advanced/metastatic non-small cell lung cancer (NSCLC) patients receiving first-line platinum doublet chemotherapy was approximately 8–12 months and 5-year survival rates were estimated at 2% (1-3).},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/28795}
}